Back to Search
Start Over
Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON-HF study.
- Source :
-
European journal of heart failure [Eur J Heart Fail] 2024 Apr; Vol. 26 (4), pp. 871-881. Date of Electronic Publication: 2024 Feb 18. - Publication Year :
- 2024
-
Abstract
- Aims: Left ventricular (LV) subclinical impairment has been described in heart failure with preserved ejection fraction (HFpEF). We assessed the relationship between LV myocardial deformation by strain imaging and recurrent hospitalization for heart failure (HF) or cardiovascular death in a large international HFpEF population.<br />Methods and Results: We assessed two-dimensional speckle-tracking based global longitudinal strain (GLS) in 790 patients (mean age 74 ± 8 years, 54% female) with adequate image quality enrolled in the PARAGON-HF echocardiography study. We examined the relationship of GLS with total HF hospitalizations and cardiovascular death (the primary composite outcome) after accounting for clinical confounders. Approximately 47% of the population had evidence of LV subclinical dysfunction, defined as absolute GLS <16%. Impaired GLS was significantly associated with higher values of circulating baseline N-terminal pro-B-type-natriuretic peptide. After a median follow-up of 3.0 years, there were 407 total HF hospitalizations and cardiovascular deaths. After multivariable adjustment, worse GLS was associated with a greater risk for the primary composite outcome (adjusted hazard ratio per 1% decrease: 1.06; 95% confidence interval 1.02-1.11; p = 0.008). GLS did not modify the treatment effect of sacubitril/valsartan compared with valsartan for the composite outcome (p for interaction >0.1).<br />Conclusions: In a large HFpEF population, impaired LV function was observed even among patients with preserved ejection fraction, and was associated with an increased risk of total HF hospitalizations or cardiovascular death, accounting for clinical confounders. These findings highlight the key role of subtle LV systolic impairment in the pathophysiology of HFpEF.<br /> (© 2024 European Society of Cardiology.)
- Subjects :
- Humans
Female
Male
Aged
Aminobutyrates therapeutic use
Biphenyl Compounds
Tetrazoles therapeutic use
Natriuretic Peptide, Brain blood
Peptide Fragments blood
Angiotensin Receptor Antagonists therapeutic use
Prognosis
Heart Ventricles physiopathology
Heart Ventricles diagnostic imaging
Aged, 80 and over
Drug Combinations
Heart Failure physiopathology
Heart Failure complications
Stroke Volume physiology
Ventricular Dysfunction, Left physiopathology
Valsartan therapeutic use
Echocardiography methods
Hospitalization statistics & numerical data
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0844
- Volume :
- 26
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- European journal of heart failure
- Publication Type :
- Academic Journal
- Accession number :
- 38369856
- Full Text :
- https://doi.org/10.1002/ejhf.3167